Artificial intelligence (AI) technology is set to transform the field of diagnostics, similar to how X-rays and genetic tests revolutionized healthcare in the past. Reshaping routine diagnostic procedures and treatment decisions and propelling pharmaceutical and research domains into new realms, AI offers significant benefits to clinicians, healthcare systems, researchers, and, most importantly, patients. This is particularly evident in cancer diagnosis and treatment across six key areas:
1.
Read More
Cancer Diagnostics
Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer
What You Should Know:
- Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.
- This partnership combines Absci's cutting-edge Integrated Drug Creation™ platform with AstraZeneca's oncology expertise, aiming to accelerate the discovery of a potential new cancer treatment.
Absci's AI Engine Takes the Lead
Absci will leverage
Read More
Ibex Medical Analytics Raises $55M to Drive AI for Cancer Diagnosis Adoption Globally
What You Should Know:
– Ibex Medical Analytics (Ibex), a provider of AI-powered cancer diagnostics raises $55M in Series C financing round led by 83North.
- The round also included participation from Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital. The financing brings total funding to over $100M since Ibex’s inception in 2016.
Read More
Ibex’s AI-Powered Cancer Diagnostics Solution Obtains CE Mark
What You Should Know:
- Ibex Medical Analytics today announced that Galen™ Prostate has become the first standalone AI-powered cancer diagnostics solution to obtain CE Mark under Vitro Diagnostic Medical Devices Regulation (IVDR) for supporting pathologists in the primary diagnosis of prostate biopsies.
- Galen Prostate is the first standalone AI-based cancer diagnostics product of its kind certified under the IVDR.
- During 2023, Ibex plans to migrate additional
Read More
Liver Cancer Awareness – Here’s What You Need to Know in 2023
By the end of 2022, nearly 42,00 new cases of primary liver cancer will be diagnosed in the United States. In fact, liver cancer incidence rates have more than tripled since 1980, marking an increased need for better detection and diagnosis.
We might not talk about liver cancer as much as we do breast or lung cancer, but it’s a real threat to millions of Americans – and we need to continue spreading awareness.
Early detection is especially critical in treating liver cancer.
Read More
Intelerad Acquires PenRad Technologies
What You Should Know:
- Today, Intelerad, a leading global provider of enterprise medical imaging solutions, announced its acquisition of PenRad, a software provider for enhancing productivity for breast imaging and lung screening.
- The acquisition expands Intelerad’s product offerings for mammography and lung analytics, ensuring radiologists, technologists and other healthcare professionals can drive greater productivity and meet higher oncology screening demand, while improving patient
Read More
Imagene Raises $21.5M to Expand Image-Based Biomarker Detection for Precision Medicine
What You Should Know:
- Imagene AI, an emerging leader in the field of AI-based precision medicine for cancer, today announced it raised $21.5 million, comprising $3M in seed funding led by Blumberg Capital and an $18.5M Series A round led by renowned technology-driven cancer medicine investors Larry Ellison, Dr. David Agus, and AI imaging space pioneer Eyal Gura.
- The use of AI-based molecular testing in cancer diagnostics is revolutionizing patient care by offering a new level of
Read More
Black Female Co-founders CancerIQ Raises $14M to Improve Cancer Early Detection and Prevention
What You Should Know:
- CancerIQ, a Chicago-based platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14M Series B financing round.
- The Series B round was co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures with participation from McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), and HealthX Ventures.
Inequality in
Read More
Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment
What You Should Know:
- Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes.
- Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development
Read More
Corindus Vascular Robotics CEO Departure, UPMC Enterprises’ New President, Nordic Consulting’s New CIO, Other Health IT Hires
Mark Toland, CEO of Corindus Vascular Robotics (acquired by Siemens for $1.1B last year), has announced his departure and will be joining BioStar Capital, a health-tech venture capital group focused on cardiovascular and orthopedic medical devices. As a partner and entrepreneur in residence, Mark will help to identify and develop innovative companies leveraging AI, deep learning, robotics, and other transformative technologies that address a wide range of unmet needs. The BioStar team has
Read More
